Open AccessEGF Receptor-Targeting Cancer Therapy Using CD47-Engineered Cell-Derived Nanoplatforms
Author(s) -
Moon Jung Choi,
Kang Chan Choi,
DoHyun Lee,
Hyun Chul Jeong,
Seong Jae Kang,
Min Woo Kim,
In Ho Jeong,
Young Myoung You,
Jin Suk Lee,
Yeon Kyung Lee,
Chang-Hwan Im,
Yong Serk Park
Publication year - 2022
Publication title -
nanotechnology, science and applications
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.051
H-Index - 28
ISSN - 1177-8903
DOI - 10.2147/nsa.s352038
Subject(s) - cd47 , nanocarriers , doxorubicin , cancer cell , cancer research , in vitro , transfection , macrophage , antibody , chemistry , drug delivery , cell , immune system , cancer , biology , immunology , medicine , chemotherapy , biochemistry , gene , organic chemistry
Avoiding phagocytic cells and reducing off-target toxicity are the primary hurdles in the clinical application of nanoparticles containing therapeutics. For overcoming these errors, in this study, nanoparticles expressing CD47 proteins inhibiting the phagocytic attack of immune cells were prepared and then evaluated as an anti-cancer drug delivery vehicle.